SEARCH

SEARCH BY CITATION

References

  • Akaike A., Takada-Takatori Y., Kume T. and Izumi Y. (2010) Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J. Mol. Neurosci. 40, 211216.
  • Akasofu S., Kosasa T., Kimura M. and Kubota A. (2003) Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur. J. Pharmacol. 472, 5763.
  • Arias E., Gallego-Sandin S., Villarroya M., Garcia A. G. and Lopez M. G. (2005) Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J. Pharmacol. Exp. Ther. 315, 13461353.
  • Chen L. J., Wang Y. J. and Tseng G. F. (2010) Compression alters kinase and phosphatase activity and tau and MAP2 phosphorylation transiently while inducing the fast adaptive dendritic remodeling of underlying cortical neurons. J. Neurotrauma 27, 16571669.
  • Del Barrio L., Martin-de-Saavedra M. D., Romero A., Parada E., Egea J., Avila J., McIntosh J. M., Wonnacott S. and Lopez M. G. (2011) Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by alpha7 and beta2* nicotinic stimulation. Toxicol. Sci. 123, 193205.
  • Eichhorn P. J., Creyghton M. P. and Bernards R. (2009) Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 1795, 115.
  • Farrimond L. E., Roberts E. and McShane R. (2012) Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ open 2, e000917.
  • Gauthier S. and Molinuevo J. L. (2013) Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement. 9, 326331.
  • Gong C. X., Grundke-Iqbal I. and Iqbal K. (1994) Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 61, 765772.
  • Gong C. X., Lidsky T., Wegiel J., Zuck L., Grundke-Iqbal I. and Iqbal K. (2000) Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J. Biol. Chem. 275, 55355544.
  • Hashiguchi M. and Hashiguchi T. (2013) Kinase-kinase interaction and modulation of tau phosphorylation. Int. Rev. Cell Mol. Biol. 300, 121160.
  • Hashimoto M., Kazui H., Matsumoto K., Nakano Y., Yasuda M. and Mori E. (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am. J. Psychiatry 162, 676682.
  • Hsu M. J., Hsu C. Y., Chen B. C., Chen M. C., Ou G. and Lin C. H. (2007) Apoptosis signal-regulating kinase 1 in amyloid beta peptide-induced cerebral endothelial cell apoptosis. J. Neurosci. 27, 57195729.
  • Janssens V. and Goris J. (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353, 417439.
  • Koh S. H., Kim S. H., Kwon H. et al. (2003) Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res. Mol. Brain Res. 118, 7281.
  • Koh S. H., Noh M. Y. and Kim S. H. (2007) Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 10, 254262.
  • Kosik K. S. (1992) Cellular aspects of Alzheimer neurofibrillary pathology. Prog. Clin. Biol. Res. 379, 183193.
  • Lahmy V., Meunier J., Malmstrom S., Naert G., Givalois L., Kim S. H., Villard V., Vamvakides A. and Maurice T. (2013) Blockade of tau hyperphosphorylation and Abeta generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. Neuropsychopharmacology. in press.
  • Lechward K., Awotunde O. S., Swiatek W. and Muszynska G. (2001) Protein phosphatase 2A: variety of forms and diversity of functions. Acta Biochim. Pol. 48, 921933.
  • Lee Y. I., Seo M., Kim Y., Kim S. Y., Kang U. G., Kim Y. S. and Juhnn Y. S. (2005) Membrane depolarization induces the undulating phosphorylation/dephosphorylation of glycogen synthase kinase 3beta, and this dephosphorylation involves protein phosphatases 2A and 2B in SH-SY5Y human neuroblastoma cells. J. Biol. Chem. 280, 2204422052.
  • Leyhe T., Hoffmann N., Stransky E. and Laske C. (2009) Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease. Int. J. Neuropsychopharmacol. 12, 13191326.
  • Lim Y. W., Yoon S. Y., Choi J. E., Kim S. M., Lee H. S., Choe H., Lee S. C. and Kim D. H. (2010) Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Biochem. Biophys. Res. Commun. 395, 207212.
  • Liu R. and Wang J. Z. (2009) Protein phosphatase 2A in Alzheimer's disease. Pathophysiology 16, 273277.
  • Liu F., Grundke-Iqbal I., Iqbal K. and Gong C. X. (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22, 19421950.
  • Longin S., Jordens J., Martens E. et al. (2004) An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator. Biochem. J. 380, 111119.
  • Min D., Mao X., Wu K. et al. (2012) Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils. Neurosci. Lett. 510, 2933.
  • Noh M. Y., Koh S. H., Kim Y., Kim H. Y., Cho G. W. and Kim S. H. (2009) Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J. Neurochem. 108, 11161125.
  • Park S. S., Jung H. J., Kim Y. J., Park T. K., Kim C., Choi H., Mook-Jung I. H., Koo E. H. and Park S. A. (2012) Asp664 cleavage of amyloid precursor protein induces tau phosphorylation by decreasing protein phosphatase 2A activity. J. Neurochem. 123, 856865.
  • Picciotto M. R. and Zoli M. (2008) Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front. Biosci. 13, 492504.
  • Plattner F., Angelo M. and Giese K. P. (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 281, 2545725465.
  • Qian W., Shi J., Yin X., Iqbal K., Grundke-Iqbal I., Gong C. X. and Liu F. (2010) PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J. Alzheimers Dis. 19, 12211229.
  • Selkoe D. J. (2004) Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med. 140, 627638.
  • Shen H., Kihara T., Hongo H., Wu X., Kem W. R., Shimohama S., Akaike A., Niidome T. and Sugimoto H. (2010) Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br. J. Pharmacol. 161, 127139.
  • Sontag E., Nunbhakdi-Craig V., Sontag J. M., Diaz-Arrastia R., Ogris E., Dayal S., Lentz S. R., Arning E. and Bottiglieri T. (2007) Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J. Neurosci. 27, 27512759.
  • Sugimoto H., Iimura Y., Yamanishi Y. and Yamatsu K. (1995) Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38, 48214829.
  • Takada Y., Yonezawa A., Kume T., Katsuki H., Kaneko S., Sugimoto H. and Akaike A. (2003) Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. 306, 772777.
  • Takada-Takatori Y., Kume T., Sugimoto M., Katsuki H., Sugimoto H. and Akaike A. (2006) Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51, 474486.
  • Takada-Takatori Y., Kume T., Ohgi Y., Izumi Y., Niidome T., Fujii T., Sugimoto H. and Akaike A. (2008) Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil. J. Neurosci. Res. 86, 35753583.
  • Vale C. and Botana L. M. (2008) Marine toxins and the cytoskeleton: okadaic acid and dinophysistoxins. FEBS J. 275, 60606066.
  • Wang J., Tung Y. C., Wang Y., Li X. T., Iqbal K. and Grundke-Iqbal I. (2001) Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett. 507, 8187.
  • Wang J. Z., Grundke-Iqbal I. and Iqbal K. (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25, 5968.
  • Xing Y., Li Z., Chen Y., Stock J. B., Jeffrey P. D. and Shi Y. (2008) Structural mechanism of demethylation and inactivation of protein phosphatase 2A. Cell 133, 154163.
  • Yin K. J., Hsu C. Y., Hu X. Y., Chen H., Chen S. W., Xu J. and Lee J. M. (2006) Protein phosphatase 2A regulates bim expression via the Akt/FKHRL1 signaling pathway in amyloid-beta peptide-induced cerebrovascular endothelial cell death. J. Neurosci. 26, 22902299.
  • Zhang C. E., Tian Q., Wei W., Peng J. H., Liu G. P., Zhou X. W., Wang Q., Wang D. W. and Wang J. Z. (2008) Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol. Aging 29, 16541665.
  • Zhou X. W., Gustafsson J. A., Tanila H., Bjorkdahl C., Liu R., Winblad B. and Pei J. J. (2008) Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol. Dis. 31, 386394.
  • Zhou X. W., Winblad B., Guan Z. and Pei J. J. (2009) Interactions between glycogen synthase kinase 3beta, protein kinase B, and protein phosphatase 2A in tau phosphorylation in mouse N2a neuroblastoma cells. J. Alzheimers Dis. 17, 929937.